CORONA Remedies Limited Q2 & H1 FY26 Concall Decoded: Freshly listed, margins flexed, and management already dreaming of 15–20% growth
1. Opening Hook
IPO confetti hadn’t even settled and CORONA Remedies was already on its maiden earnings call, confidently telling investors: “Relax, we’ve been doing this for 21 years.” Fresh listing glow, sharp suits, and a surprisingly calm management tone—this was less debutant nerves and more “experienced middle-order batsman” energy.
The call mixed philosophy (Triple C, anyone?), disciplined execution, and just enough ambition to keep growth investors awake. Revenue grew faster than IPM, margins expanded post-listing, and management casually dropped a 15% revenue and 20% PAT CAGR guidance like it was standard operating procedure.
Read on—because behind the culture talk and ESG slides lies a pharma company quietly building scale, brands, and optionality.
2. At a Glance
Revenue up 15.1% (Q2) – IPO or not, growth didn’t take a tea break.
EBITDA margin at 21.7% – Quietly best-in-class territory.
PAT up 21.8% – Profits growing faster than sales, always a good sign.
70% chronic mix – Seasonality politely shown the exit door.
Net cash company – Balance sheet behaving like an adult.
3. Management’s Key Commentary
“Culture is the first C—ruthless execution defines us.” (Translation: We don’t blame markets 😏)
“We have outpaced IPM by 1.5x consistently.” (Translation: Benchmarks are meant to be beaten.)
“38 brands generate over ₹10 crore annually.” (Translation: This isn’t a one-brand wonder.)
“Infertility will be unlocked next with a dedicated team.” (Translation: New growth engine warming up 🚀)
“We aim for 15% revenue and 20% PAT CAGR.” (Translation: High confidence, now deliver.)
“We are net cash with strong EBITDA-to-OCF conversion.” (Translation: Cash is real, not Excel-based.)
